High expression of () predicts unfavorable survival outcomes in breast cancer.

is associated with several cancers, but its biomarker potential in breast cancer is not adequately known. Q-RT-PCR, immunohistochemistry, COBRA methods and tools (KM-Plotter, UALCAN) were used to analyze the expression level, methylation status and prognostic value of in breast cancer. expression was significantly higher in clinical tumor samples compared with normal samples. High mRNA expression is associated with poor survival values in breast cancer. promoter region is hypomethylated in cell lines and clinical samples. High expression predicts poor clinical survival outcomes for breast cancer. Other than promoter methylation, epigenetic factors also warrant investigation in future studies as a regulatory mechanism of expression in breast cancer.